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A B S T R A C T
Pathophysiological bone resorption is commonly associated with periodontal disease and involves the excessive
resorption of bone matrix by activated osteoclasts. Receptor activator of nuclear factor (NF)-κB ligand (RANKL)
signaling pathways have been proposed as targets for inhibiting osteoclast differentiation and bone resorption.
The fungal secondary metabolite (+)-terrein is a natural compound derived from Aspergillus terreus that has
previously shown anti-interleukin-6 properties related to inflammatory bone resorption. However, its effects and
molecular mechanism of action on osteoclastogenesis and bone resorption remain unclear. In the present study,
we showed that 10 µM synthetic (+)-terrein inhibited RANKL-induced osteoclast formation and bone resorption
in a dose-dependent manner and without cytotoxicity. RANKL-induced messenger RNA expression of osteoclast-
specific markers including nuclear factor of activated T-cells cytoplasmic 1 (NFATc1), the master regulator of
osteoclastogenesis, cathepsin K, tartrate-resistant acid phosphatase (Trap) was completely inhibited by synthetic
(+)-terrein treatment. Furthermore, synthetic (+)-terrein decreased RANKL-induced NFATc1 protein expres-
sion. This study revealed that synthetic (+)-terrein attenuated osteoclast formation and bone resorption by
mediating RANKL signaling pathways, especially NFATc1, and indicated the potential effect of (+)-terrein on
inflammatory bone resorption including periodontal disease.
1. Introduction
Osteoclasts are bone-resorptive, multi-nucleated cells derived from
hematopoietic stem cells of the monocyte/macrophage lineage.
Together with osteoblasts, osteoclasts are involved in bone homeostasis
[1]. Receptor activator of nuclear factor (NF)-κB ligand (RANKL) and
macrophage colony-stimulating factor (M-CSF) are two critical factors
supplied by osteoblasts that are essential for the differentiation and
maturation of osteoclast precursors [2]. During bone resorption, os-
teoclasts are highly polarized, form tightly sealed compartments on the
bone surface, and secrete protons and proteases such as cathepsin K
from the ruffled border, resulting in the degradation of bone matrix [1].
The abnormal enhancement of osteoclasts is therefore implicated in a
variety of inflammatory bone resorptive diseases, including rheumatoid
arthritis, osteoporosis, and periodontal disease [3–5].
Osteoclast-targeting small molecule inhibitors show potential as
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therapeutic drugs for bone-related diseases. Bisphosphonates, synthetic
analogs of pyrophosphate, are currently the most important and effec-
tive anti-resorptive drugs commercially available, and established as
the treatments of choice for various diseases of excessive bone resorp-
tion, including Paget's disease of bone, the skeletal complications of
malignancy, and osteoporosis [6]. However, medicine-related osteo-
necrosis of the jaw (MRONJ) was reported as one of the serious side
effects of bisphosphonate therapy, thus reducing the quality of life of
patients receiving such treatment [7]. There is therefore a critical need
to develop novel, safe, and effective host modulation treatments to
prevent and treat inflammatory bone destructive diseases.
(+)-Terrein is a bioactive fungal secondary metabolite that was first
isolated from Aspergillus terreus in 1935 (Fig. 1A) [8]. Various biological
properties of (+)-terrein have been reported, including antibacterial
activities [9], inhibition of angiogenin secretion in prostate cancer cells
[10] and head/neck cancer [11], anti-inflammatory immune modula-
tion in pulpal inflammation [12], and inhibition of biofilm formation
[13]. Furthermore, we previously reported the effects of synthetic
(+)-terrein on anti-interleukin (IL)-6 signaling and inhibition of vas-
cular endothelial growth factor (VEGF) and M-CSF secretion in human
gingival fibroblasts (HGFs) [14,15]. IL-6 is an important pro-in-
flammatory cytokine that induces a wide variety of biological effects
including inflammatory bone resorption in rheumatoid arthritis [17]
and periodontal disease [18]. We demonstrated that (+)-terrein may be
a useful tool in regulating IL-6-associated inflammatory bone resorp-
tion, although the precise effects and functional mechanism of
(+)-terrein on osteoclastogenesis remain unclear.
In this study, we aimed to investigate the effects of synthetic
(+)-terrein on RANKL-induced osteoclastogenesis using mouse bone
marrow macrophages (BMMs). Our results suggest that host modulation
using synthetic (+)-terrein may be a novel therapeutic modality for the
prevention of inflammatory bone destruction in patients with period-
ontal disease.
2. Material and methods
2.1. Reagents
(+)-Terrein was synthesized from dimethyl L-tartrate. All spectra
(1H and 13C nuclear magnetic resonance (NMR) spectra, infrared (IR))
and specific rotation of synthetic (+)-terrein were similar to those of
natural (+)-terrein and those previously described [14]. The following
were used: human soluble RANKL (Wako, Hiroshima, Japan), human
M-CSF (Leucoprol, Kyowa Hakko Kogyo, Japan), mouse TNF-α (R&D
systems, Minneapolis, MN, USA), rabbit anti-nuclear factor of activated
T-cells cytoplasmic 1 (NFATc1) monoclonal antibody (Santa Cruz Bio-
technology, Dallas, TX, USA), rabbit anti-phospho ERK1/2, p38-MAPK,
and NF-κB p65 monoclonal antibodies (Cell Signaling Technology
Danvers, MA, USA), and mouse anti-β-actin monoclonal antibody
(Sigma-Aldrich, St. Louis, MO, USA).
2.2. Cell preparation and cell viability assay
Five-week-old male C57BL6/J mice were obtained from Japan CLEA
(Japan). Bone marrow cells were collected from the tibiae and femora
and were cultured with M-CSF (50 ng/mL) for 3 days in culture dishes
containing DMEM (Wako) supplemented with 10% fetal bovine serum
(FBS, Invitrogen, Carlsbad, CA, USA). After 3 days, floating cells were
Fig. 1. (A) Chemical structure of (+)-terrein; (B) Representative images of a 48-well plate showing the effects of synthetic (+)-terrein (0.01, 1, and 10 µM) on
RANKL or TNF-α induced bone marrow macrophage (BMM)-derived osteoclast-like cell formation stained with tartrate-resistant acid phosphate (TRAP). The cells
were photographed (original magnification, 100×, scale bar = 100 µm); (C) Analysis of the number of TRAP-positive cells formed in the presence or absence of
synthetic (+)-terrein (10 µM). The cells were photographed (original magnification, 100×, scale bar = 100 µm) and TRAP-positive, multinucleated (> 3 nuclei)
osteoclasts were counted. Columns represent the mean results of experiments carried out in triplicate and bars represent the standard division (SD) (n = 3,
*p < 0.05). and (D) Effect of synthetic (+)-terrein on cell viability as assessed via MTS assay (n = 3, *p < 0.05, control: without (+)-terrein).
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removed by rinsing with phosphate buffered saline (PBS) and attached
cells were used as BMMs [18]. Cell viability was evaluated using an
MTS assay kit (Promega, Madison, WI, USA). BMMs were seeded at a
density of 1 × 104 cells in 100 μL medium in 96-well plates and in-
cubated for 1 day at 37 °C in DMEM containing 10% FBS, M-CSF
(100 ng/mL), and RANKL (100 ng/mL). At the same time, (+)-terrein
was diluted to concentrations of 0.01–1000 μM. The medium was then
removed and 20 μL MTS was added to the wells. Cells were incubated at
37 °C for 4 h to allow the color to develop. Optical density was mea-
sured at 490 nm using a microtiter plate-reader (Bio-Rad, Hercules, CA,
USA). All animal experiments were performed in accordance with the
Guidelines for Proper Conduct of Animal Experiments of the Science
Councils of Japan and approved by the Animal Research Control
Committee of Okayama University (approval no. OKU-2016277).
2.3. Osteoclast formation
To induce osteoclast differentiation, BMMs were further cultured
with RANKL (100 ng/mL) and M-CSF (100 ng/mL) in the presence and
absence of (+)-terrein (0.1–10 µM) for 5 days. Cells were then fixed in
4% paraformaldehyde and stained for tartrate-resistant acidic phos-
phatase (TRAP). TRAP-positive multinucleated cells containing more
than three nuclei were considered osteoclasts.
2.4. Real-time polymerase chain reaction (PCR)
BMMs (1.0 × 105/cm2) were harvested to a 12 well-plate, and
treated with RANKL (100 ng/mL) and M-CSF (100 ng/mL) in the pre-
sence and absence of (+)-terrein (10 µM) for 1 or 2 days. Total ribo-
nucleic acid (RNA) was then isolated using an RNeasy® Mini Kit
(Qiagen, Hilden, Germany), followed by deoxyribonucleic acid (DNA)
removal using an RNase-free DNase kit (Qiagen). A total of 1 μg high-
quality total RNA was then reverse-transcribed using the SuperScript®
III First-Strand Synthesis System (Thermo Fisher Scientific, Waltham,
MA, USA). Amplification reactions were performed using SYBR® green
PCR Master Mix (Thermo Fisher Scientific). Up to 1 ng complimentary
(c)DNA was then amplified using specific primers. Reactions were
performed using a 7300 Real-Time PCR System (Thermo Fisher
Scientific). Ratios of messenger (m)RNA levels to control values were
calculated using the ΔCt method (2−ΔΔCt). All data were normalized to
the housekeeper control gene, β-actin. PCR conditions used were as
follows: maintained for 10 min at 95 °C, followed by 40 cycles of 15 s at
95 °C, and 60 s at 60 °C. The primers used were as follows: 5′-CTCGA
AAGACAGCACTGGAGCCAT-3′ (forward) and 5′-CGGCTGCCTTCCGTC
TCATAG-3′ (reverse) for Nfatc1, 5′-TGACCACTGCCTTCCAATACG-3′
(forward) and 5′-TGCATTTAGCTGCCTTTGCC-3′ (reverse) for cathepsin
K, 5′-ATGCCAGCGACAAGAGGTTC-3′ (forward) and 5′-TGGTTTCCAG
CCAGCACATAC-3′ (reverse) for Trap (Acp5), 5′-CCTTGGAAAGCTAGA
AGCACAC-3′ (forward) and 5′-AAGAGGAGCAGAACGATGAGAC-3′
(reverse) for RANK and 5′-TAGCGGAACCGCTCATTGCC-3′ (forward)
and 5′-TTCACCCACACTGTGCCC-3′ (reverse) for β-actin [19].
2.5. Western blotting
BMMs (1.0 × 105/cm2) were harvested to a 12 well-plate, and
treated with RANKL (100 ng/mL) and M-CSF (100 ng/mL) in the pre-
sence and absence of (+)-terrein (10 µM) for 2 days (for detecting
NFATc1 expression), 10–30 min (for detecting phospho-ERK1/2,
phospho-p38 MAPK, phospho-NF-κB expression). After each time
course, cells were lysed rapidly by the addition of ice-cold cell lysis
buffer containing 50 mM NaCl, 10 mM Tris-HCl (pH 7.2), 1% Nonidet
P-40, 5 mM EDTA-Na, 1 mM sodium ortho vanadate, 1% sodium do-
decyl sulfate (SDS), and protease inhibitor cocktail (Sigma-Aldrich) for
10 min, according to a method previously described [20]. Protein
concentration was determined via Bradford assay using bovine serum
albumin (BSA, Sigma-Aldrich) as the standard. The lysates (30 µg) were
mixed with SDS sample buffer (1% (w/v) SDS, 45 mM Tris-HCl (pH
6.8), 15% (v/v) glycerol, 144 mM 2-mercaptoethanol, and 0.002%
bromophenol blue) and samples were boiled for 5 min. The samples
were separated via SDS-polyacrylamide gel electrophoresis (PAGE) on
7.5% or 12% polyacrylamide slab gels, and transferred onto poly-
vinylidene difluoride membranes. Membranes were blocked with 5%
skim milk in Tris-buffered saline with Tween 20® (TBST; 20 mM Tris-
HCl (pH 7.6) containing 150 mM NaCl and 0.1% (v/v) Tween 20®) for
1 h and incubated with anti-NFATc1 monoclonal antibody (1:1000),
anti-phospho-ERK1/2 (1:1000), anti-phospho-p38 MAPK (1:1000),
anti-phospho-NF-κB (1:1000) overnight at 4 °C. The membranes were
incubated with secondary antibodies (goat anti-rabbit immunoglobulin
G (IgG)-horse-radish peroxidase (HRP) conjugate, 1:2000 dilution; GE
Healthcare, Chicago, IL, USA) for 1 h. HRP activity was visualized by
incubating membranes in an electrochemiluminescence (ECL) detection
system (SuperSignal® West Dura Extended Duration Substrate, Thermo
Fisher Scientific) followed by autoradiography. At the end of these
experiments, the immunodetection system and the bound antibody
were removed from the blots by incubating the membranes with re-
probing buffer (RestoreTM Western Blot Stripping Buffer, Thermo Fisher
Scientific). The blots were then stained with anti-β-actin antibody (1:10
000 dilution) to confirm that equal amounts of protein were present in
each lane of the gel.
2.6. Resorption assay
BMMs (1 × 104 cells) were cultured for 7 days with M-CSF (100 ng/
mL) and RANKL (100 ng/mL) in the presence and absence of (+)-ter-
rein (10 µM) in 96-well, flat-bottomed osteo assay plates (Corning Inc.,
Corning, NY, USA). To quantitate resorption lacunae, cells were re-
moved using 5% sodium hypochlorite, followed by extensive washing
with distilled water and air-drying. The absorbed areas on the well were
observed under a microscope and quantified at least 6 wells per con-
dition using Image J software (National Institutes of Health, NIH).
2.7. Statistical analysis
Experimental results are presented as means ± standard deviation
(SD). Multiple comparisons were conducted via one-way analysis of
variance (ANOVA) and Tukey test. p < 0.05 was considered statisti-
cally significant.
3. Results
3.1. Synthetic (+)-terrein suppressed osteoclastogenesis
Osteoclastogenesis assays were performed to investigate the effects
of synthetic (+)-terrein on the formation of TRAP-positive, multi-
nucleated osteoclasts. Treatment with synthetic (+)-terrein resulted in
the dose-dependent inhibition of RANKL-induced osteoclast formation,
especially in the 10 µM synthetic (+)-terrein-treated group (p < 0.05,
Fig. 1B and C). In addition, 10 µM synthetic (+)-terrein also inhibited
TNF-α induced osteoclast differentiation (Fig. 1B). Cell viability was
assessed via MTS cell proliferation assay. No cytotoxic effects were
observed in BMMs cultured with ≤100 µM (+)-terrein (Fig. 1D) and
the inhibitory effects of (+)-terrein on osteoclast formation were
therefore not due to cytotoxicity.
3.2. Synthetic (+)-terrein suppressed RANKL-induced osteoclast function
To investigate the direct effects of synthetic (+)-terrein on osteo-
clast resorptive function, RANKL-treated BMM-derived osteoclasts were
seeded on hydroxyapatite-coated multiwell plates and treated with
synthetic (+)-terrein for 7 days. Analysis of hydroxyapatite resorption
pits (Fig. 2A) revealed that the resorbed area was significantly de-
creased in the presence of synthetic (+)-terrein compared to that in the
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untreated control group (p < 0.05, Fig. 2B).
3.3. Synthetic (+)-terrein inhibited RANKL-induced NFATc1 expression
and related osteoclastogenesis related cathepsin K and Trap mRNA
expression
In response to the stimulatory effects of RANKL, osteoclast differ-
entiation was associated with up-regulation of NFATc1. As shown via
quantitative real-time PCR, RANKL dramatically induced NFATc1
mRNA expression in the untreated group (p < 0.05, Fig. 3A). How-
ever, synthetic (+)-terrein (10 µM) significantly suppressed NFATc1
expression (p < 0.05, Fig. 3A). At the protein level, addition of RANKL
increased NFATc1 expression (p < 0.05, Fig. 3B), indicating that the
NFATc1 signaling cascade was triggered during osteoclastogenesis.
Conversely, synthetic (+)-terrein significantly inhibited RANKL-in-
duced NFATc1 protein expression (p < 0.05, Fig. 3B). In addition,
RANKL dramatically induced osteoclastogenic factors mRNA expres-
sion, cathepsin K and Trap, downstream of NFATc1 (p < 0.05, Fig. 4).
However, synthetic (+)-terrein (10 µM) significantly suppressed ca-
thepsin K and Trap expression (p < 0.05, Fig. 4). While, RANKL and
synthetic (+)-terrein did not affect the RANK expression (Fig. 4).
3.4. Synthetic (+)-terrein suppressed osteoclast differentiation even after
RANKL initiation
To investigate the effects of synthetic (+)-terrein on RANKL-in-
duced osteoclastogenesis at different time-points, synthetic (+)-terrein
(10 μM) was added to the culture medium on days 0, 1, or 2 after
Fig. 2. (A) Synthetic (+)-terrein inhibited RANKL-induced hydroxyapatite resorption. Mouse BMMs (1 × 104 cells/well) were seeded into osteo assay plates and
treated with RANKL/M-CSF (100 ng/mL each), in the presence and absence of synthetic (+)-terrein (10 μM), for 7 days. After incubation, images were obtained
using a light microscope (original magnification, 200×, scale bar = 10 μm). Representative images of resorption pits are shown. (B) Representative resorption pit
areas were measured using Image J software. Columns represent the means of experiments carried out at least 6 wells per condition, and bars represent the SD
(n = 6, *p < 0.05).
Fig. 3. (A) Synthetic (+)-terrein inhibited RANKL-induced NFATc1 mRNA expression. Mouse BMMs (1 × 105 cells/well) were incubated in serum-free medium
containing RANKL/M-CSF (100 ng/mL each) in the presence and absence of synthetic (+)-terrein (10 μM) for 24 h. Cells were lysed and total RNA was subjected to
real-time reverse transcription polymerase chain reaction (RT-PCR) for determination of NFATc1 gene expression. Columns represent the mean relative intensity of
experiments carried out in triplicate and bars represent the SD (n = 3, *p < 0.05). (B) Synthetic (+)-terrein inhibited RANKL-induced NFATc1 protein expression.
Mouse BMMs (1 × 105 cells/well) were treated with RANKL/M-CSF (100 ng/mL each) in the presence and absence of synthetic (+)-terrein (10 μM) for 24 h or were
left untreated (controls). Total cell extracts were prepared and subjected to Western blotting using anti-NFATc1 and β-actin. Relative density was measured using
Image J software. Columns represent the mean results of experiments carried out in triplicate and bars represent the SD (n = 3, *p < 0.05).
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RANKL stimulation. The maximum inhibitory effects of synthetic
(+)-terrein against osteoclastogenesis were observed when synthetic
(+)-terrein was added to the culture at the same time as RANKL
(Fig. 5A). Exposure of precursor cells to synthetic (+)-terrein at later
stages (1 or 2 days after RANKL stimulation) resulted in less effective
suppression of osteoclast-induced NFATc1 protein expression
(p < 0.05, Fig. 5B).
3.5. Synthetic (+)-terrein did not suppress RANKL-induced ERK1/2, p38
MAPK and NF-κB protein phosphorylation
To investigate the effects of synthetic (+)-terrein on RANKL sig-
naling cascade during the osteoclast differentiation, synthetic (+)-ter-
rein (10 μM) was added to the culture medium on 30 min before RANKL
stimulation. Addition of RANKL-induced protein phosphorylation of
ERK1/2, p38 MAPK and NF-κB p65 (Fig. 6), indicating that the RANKL
signaling cascade was triggered during osteoclastogenesis. However,
synthetic (+)-terrein did not suppress RANKL-induced protein phos-
phorylation of ERK1/2, p38 MAPK and NF-κB p65 (Fig. 6).
4. Discussion
In this study, we demonstrated that synthetic (+)-terrein sup-
pressed osteoclastogenesis in mouse BMMs. In addition, synthetic
(+)-terrein suppressed RANKL-induced expression of NFATc1, a master
transcriptional factor for osteoclastogenesis, and related osteoclasto-
genic factors, including cathepsin K and Trap. These findings suggest
that (+)-terrein may play an important role in suppressing NFATc1
expression, regulating RANKL-induced osteoclastogenesis, and mod-
ulating inflammatory bone resorption including periodontal disease.
Excessive bone resorption due to an imbalance between osteoblast
and osteoclast activity is characteristic of inflammatory bone resorptive
diseases such as periodontal disease. Excessive bone resorption is often
caused by increased RANKL levels and subsequent expression of its
related downstream genes, and this pathway was therefore confirmed
as a useful target for the treatment of osteolytic bone diseases [21,22].
Unlike bisphosphonates, natural compounds exhibit their potential ef-
fects by inhibiting osteoclastogenesis and RANKL signaling pathways.
Natural compounds present several advantages over current anti-os-
teolytic treatments such as bisphosphonates and hormone replacement
therapies, which may cause severe side effects including MRONJ
[23–25]. In this study, we demonstrated that (+)-terrein, a natural
secondary bioactive fungal metabolite derived from A. terreus, inhibited
osteoclast formation and associated resorption by blocking RANKL-in-
duced NFATc1 activities. This indicates that synthetic (+)-terrein may
be used as a therapeutic agent to prevent bone resorption in osteolytic
bone diseases such as rheumatoid arthritis and periodontal disease.
Various biological properties of (+)-terrein have been reported,
including antibacterial [9] and anti-inflammatory, immunomodulatory
activities [12,14]. Furthermore, we previously reported the effects of
synthetic (+)-terrein on the IL-6 signaling cascade, including inhibition
of Janus activated kinase 1 (JAK1) phosphorylation in HGFs [15]. IL-6,
as well as TNF-α, is an important pro-inflammatory cytokine that in-
duces a wide variety of biological effects including inflammatory bone
resorption in rheumatoid arthritis and periodontal disease [16,17].
Here, we showed that synthetic (+)-terrein is a novel and promising
compound for the inhibition of RANKL- and TNF-α-induced osteoclas-
togenesis (Fig. 1). A recent study revealed that (+)-terrein plays a
significant role in suppressing oxidative stress, thus conferring a pro-
tective effect on cells and reducing inflammatory molecules in human
diploid fibroblasts [26]. Oxidative stress regulates the development of
osteoporosis and enhanced osteoclast formation and function [27]. As
Fig. 4. (A) Synthetic (+)-terrein inhibited RANKL-induced cathepsin K and Trap mRNA expression. Mouse BMMs (1 × 105 cells/well) were incubated in serum-free
medium containing RANKL/M-CSF (100 ng/mL each) in the presence and absence of synthetic (+)-terrein (10 μM) for 48 h. Cells were lysed and total RNA was
subjected to real-time reverse transcription polymerase chain reaction (RT-PCR) for determination of cathepsin K, Trap(Acp5), RANK gene expression. Columns
represent the mean relative intensity of cathepsin K, Trap, RANK compared to that of β-actin carried out in triplicate and bars represent the SD (n = 3, *p < 0.05).
S. Nakagawa, et al. International Immunopharmacology 83 (2020) 106429
5
RANKL and TNF-α may induce oxidative responses [28,29], it is likely
that (+)-terrein has inhibitory effects on RANKL- and TNF-α-induced
oxidative stress and osteoclastogenesis.
Osteoclasts formation is triggered by the differentiation and fusion
of macrophage precursor cells [22]. RANKL belongs to the tumor ne-
crosis factor family and is the key regulator of bone resorption. RANKL
binds with RANK, which activates the downstream signaling pathways
regulating osteoclastogenesis [30], including calcium-regulated
NFATc1 activity [31]. NFATc1 is a master transcription factor mod-
ulating osteoclast differentiation [32] whose activation is dependent on
downstream NF-κB activation. NFATc1 nuclear translocation is also
mediated by activated calcium signaling and NFATc1 expression is
promoted by NFAT itself via automated feedback [33]. Induced
NFATc1 in turn drives the expression of a number of osteoclastogenic
genes including dendritic cell-specific transmembrane protein
(Dcstamp), v-type protein ATPase subunit d2 (Atp6v0d2), osteoclast-
associated receptor (Oscar), integrin β3 (Itgb3), osteoclast stimulatory
transmembrane protein (Ocstamp), tartrate-resistant acid phosphatase
(Acp5), calcitonin receptor (Calcr), and cathepsin K (Ctsk) [34].
NFATc1 improved the expression of these genes to promote cellular
differentiation and function [34].
In the present study, we showed that RANKL-induced NFATc1
transcriptional activity and NFATc1 protein levels and related osteo-
clastogenic genes (cathepsin K and Trap) were dramatically inhibited by
synthetic (+)-terrein (Figs. 3, 4). In addition, delayed application of
synthetic (+)-terrein also inhibited RANKL-induced osteoclastogenesis
(Fig. 5). However, synthetic (+)-terrein did not suppress RANKL-in-
duced NF-κB and MAPKs phosphorylation (Fig. 6). This may be via
direct intervention in the NFATc1 activation pathway or suppression of
another RANKL signaling cascade, Ca2+-calmodulin pathway, upstream
of NFATc1 activity, required further investigation. These results suggest
that (+)-terrein inhibits osteoclast differentiation through NFATc1-
mediated pathways. However, reports concerning the role of (+)-ter-
rein on osteoblasts are limited to the fact that (+)-terrein enhanced
osteoblasts attachment to a titanium plate [35]. Therefore, the effects of
(+)-terrein on osteoblasts require further investigation.
In the present study, we used synthetic (+)-terrein produced from
dimethyl L-tartrate. All spectra (1H and 13C NMR, IR) and the specific
rotation of synthetic (+)-terrein were similar to those of natural
(+)-terrein [14]. Synthesized (+)-terrein presents several significant
features: it can be orally administered because of its low molecular
weight, has a short half-life, and has a low production cost compared to
that of biological products containing natural (+)-terrein extracted
from A. terreus. The results of the present study provide new insight into
the potential of synthetic (+)-terrein to inhibit osteoclastogenesis.
However, additional studies should be performed to examine the mo-
lecular targets of (+)-terrein in the cytosol.
In summary, the present study demonstrated that synthetic
(+)-terrein reduced osteoclast formation and bone resorption by in-
terfering with RANKL-induced NFATc1 activation. The results of this
study have provided new insight into the potential use of synthetic
(+)-terrein as an anti-resorptive agent for the treatment of osteolytic
Fig. 5. Delayed addition of synthetic (+)-terrein inhibited RANKL-induced osteoclastogenesis. (A) Mouse BMMs (1 × 105 cells/well) were incubated with RANKL/
M-CSF (100 ng/mL each) and synthetic (+)-terrein (10 μM) was subsequently added at 0, 24, or 48 h. After 5 days (120 h), cells were stained to measure TRAP
expression. The cells were photographed (original magnification, 100 × ) and TRAP-positive, multinucleated osteoclasts were counted. Columns represent the mean
results of experiments carried out in triplicate and bars represent the SD (n = 3, *p < 0.05). (B) RANKL-induced NFATc1 expression was assessed via Western
blotting. Mouse BMMs (1 × 105 cells/well) were treated with RANKL/M-CSF (100 ng/mL each) and synthetic (+)-terrein (10 μM) was subsequently added at 0 and
24 h. Total cell extracts were prepared and subjected to Western blotting using anti-NFATc1 and β-actin. Relative density was measured using Image J software.
Columns represent the mean results of experiments carried out in triplicate and bars represent the SD (n = 3, *p < 0.05).
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bone diseases including periodontal disease.
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